Kalaris Therapeutics (KLRS) Exchange Rate Effect (2020 - 2021)
Kalaris Therapeutics (KLRS) posted quarterly Exchange Rate Effect of -$105000.0 for Q3 2021, down 377.27% quarter-over-quarter from -$22000.0 in Q2 2021.
Kalaris Therapeutics (KLRS) Exchange Rate Effect (2020 - 2021) Analysis & Trends
Kalaris Therapeutics' Exchange Rate Effect history runs 2 years deep, the most recent figure standing at -$105000.0 for Q3 2021.
- In Q3 2021, Exchange Rate Effect changed N/A year-over-year to -$105000.0; the TTM figure through Dec 2021 stood at -$44000.0 (changed N/A YoY), while the FY2021 annual figure was -$44000.0, up 51.11% from the prior year.
- Exchange Rate Effect for Q3 2021 stood at -$105000.0, down from -$22000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $83000.0 in Q1 2021, with the low at -$105000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Kalaris Therapeutics | 98.76 Mn | 98.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -105,000.00 |
| Sep 30, 2021 | -105,000.00 |
| Jun 30, 2021 | -22,000.00 |
| Jun 30, 2021 | -22,000.00 |
| Mar 31, 2021 | 83,000.00 |
| Mar 31, 2021 | 83,000.00 |
| Dec 31, 2020 | -64,000.00 |
| Dec 31, 2020 | -64,000.00 |